Urology Times staff

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Denise Asafu-Adjei, MD, MPH, discusses the development of microsurgical testicular sperm extraction.

"Micro TESE is associated with higher sperm retrieval rates compared with conventional testicular sperm extraction, so this approach has really become the gold standard for sperm extraction in patients with non-obstructive azoospermia," says Denise Asafu-Adjei, MD, MPH.

“Mitomycin gel, or Jelmyto, is the first agent that gives us a chance to be able to treat these low-grade upper tract cancers of the ureter and the kidney and prevent their recurrence,” says Munver.

"This non face-to-face care coordination done 'incident to' to the provider...is reimbursable through chronic care management codes," says Shirley Lee, CRNP-FNP, MPH.

The sNDA is based on findings from the phase 3 ARASENS trial, which showed that adding darolutamide to standard ADT boosted overall survival in patients with mHSPC.

“Getting people to work together towards a common goal is really, really important in alleviating the imposter syndrome,” says Toby C. Chai, MD.

“We really need to listen to what people care about and speak to that,” says Shirley Lee, CRNP-FNP, MPH.

“As urologists, we see men of all ages, and one of the things that we need to do is…take advantage of being their advocates for health care,” says Michael Lutz, MD.

“Any kind of complicated cancer surgery requires an experienced team from beginning to end,” says David Lee, MD.

“We had fantastic completion of the study, and we were very pleased with the results,” says Samantha Pulliam, MD.

"β3 agonists really provided a new drug class of medications for patients with overactive bladder. Previously, there were no alternatives," says Ekene Enemchukwu, MD, MPH.

“We talked about patient buy in but family caregiver buy in is just as important, especially when we're talking about cancer,” says Shirley Lee, CRNP-FNP.

“In urology, and really medicine as a whole, I think we're all really striving to build that championship-caliber team, and we're looking at recruiting diverse talent, but if we don't take the time to create the environments where all the team members can reach their full potential, then we as a whole may never reach our full potential in medicine,” says Ekene Enemchukwu, MD, MPH.

“This is a unique device in that it shows motion-based biofeedback,” says Samantha Pulliam, MD.

“We…just need to apply operational efficiencies that are utilized in other industries [to] health care,” says Shirley Lee, CRNP-FNP, MPH.

“Status quo EHR [and] status quo documenting [are] not going to give us the insights that we really need about how [patients are] doing now, and what are the opportunities we have to improve their care,” says Shirley Lee, CRNP-FNP, MPH.

“Clinically speaking, it really can harm patients to have gaps in both the data and their care,” says Shirley Lee, CRNP-FNP, MPH.

At standard stimulation parameters, the Axonics F15 system is expected to function for 15+ years; at lower energy settings, this extends to 20+ years.

"I would say our greatest advance of the past 30 years is our clinical trials infrastructure, because we can now use our therapies with intelligence," says Anthony Zietman, MD.

“Overall, there's no known advantage or disadvantage in a head-to-head trial of either one of these, but I do think they're complementary,” says Scott T. Tagawa, MD, when discussing radium-223 dichloride and lutetium Lu 177 vipivotide tetraxetan.

“If approved, tebipenem could provide a new oral treatment option for patients with cUTI who have limited or no alternative oral options," says Angela Talley, MD.

“I think we are good at treating the cancer but maybe not great at treating the patient as a whole. And that is an area that we can improve going forward based on research like this,” says Amy N. Luckenbaugh, MD.

In this conversation, Acacia Brush Perko, Esq, and Kenton H. Steele, Esq, discuss the qualities that comprise a good expert witness in a malpractice lawsuit.

“I think that the utilization of social media for professionals is only going to grow. And I would really encourage people at every level to start to dip their toe in the water and explore Twitter or other social media platforms,” says Casey Seideman, MD.

“We kind of expected that treatment type wouldn't make a ton of difference in terms of…mental health outcomes after either surgery or radiation…but we were very clearly able to find groups of people who were at risk for poor mental health outcomes,” says Amy N. Luckenbaugh, MD.

“Oral tebipenem pivoxil hydrobromide and intravenous ertapenem had a similar safety and tolerability profile,” says Angela Talley, MD.

"Now, men have the option to seek out something minimally invasive before surgical options are breached," says Denise Asafu-Adjei, MD, MPH.

"Peyronie's disease has really seen a wide range of intralesional options through the years," says Denise Asafu-Adjei, MD, MPH.

“I think the take home message is not to take sacral neuromodulation off the table,” says Sarah Martin, DO.

“The take-home message is that there is a new form of lithotripsy,” says Jonathan D. Harper, MD.